Laekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2a for the Treatment of Obesity

Like
Comment
Favorite

Laekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2a for the Treatment of Obesity

THOMSON REUTERS2024-11-20

Laekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2a for the Treatment of Obesity

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

抱歉，当前请求异常(-1)

7x24

All

19:32
Investigation Will Focus on Electrical Distribution Equipment - London Fire Brigade
19:32
Fire at Substation Near Heathrow Airport Is Believed to Be Non-Suspicious - London Fire Brigade
19:28
Cftc-Speculators Increase Cbot US 5-Year Treasury Futures Net Short Position by 32,573 Contracts to 1,905,940 in Week on March 18
19:28
Cftc-Speculators Trim Cbot US 2-Year Treasury Futures Net Short Position by 1,659 Contracts to 1,220,556 in Week on March 18
19:27
Cftc- Euro Net Long Position Is 59,425 Contracts in Week Ended Mar 18 2025

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2484110931?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2024-11-20 22:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484110931","market":"us","top_or_hot":-1,"title":"Laekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2a for the Treatment of Obesity","media":"THOMSON REUTERS","content":"<html><body><p>Laekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2a for the Treatment of Obesity</p></body></html>","source":"reuters_en_live","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Laekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2a for the Treatment of Obesity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLaekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2a for the Treatment of Obesity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-20 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA8JSTS0:1><strong>THOMSON REUTERS</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Laekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2a for the Treatment of Obesity</p>\n\n<a href=\"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA8JSTS0:1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241120:nTUA8JSTS0:1","article_id":"2484110931","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484110931","pubTimestamp":1732111227,"columns":[],"sourceInfo":{"source_id":"reuters_en_live","name":"Thomson Reuters"},"weMediaInfo":null,"summary":"Laekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody ","collect":0,"end_time":0,"defaultTopTitle":"refinitiv.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02105":"来凯医药-B"},"translate_title":"Laekna宣布与礼来开展临床合作，开发针对激活素受体2a型的新型单克隆抗体Lae102，用于治疗肥胖症","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":0.9},"content_text":"Laekna Announces a Clinical Collaboration With Lilly to Develop Lae102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2a for the Treatment of Obesity","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}